Know Your Ports - Oncology Nursing News
Dec 21, 2017 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters such as Mediports.
Low-Dose Tamoxifen Shows Continued Efficacy in Adjuvant …
Feb 17, 2023 · Tamoxifen, at a dose of 5 mg daily (babytam), continued to show a benefit over placebo in reducing the risk of recurrence from invasive breast cancers and ductal carcinoma in situ (DCIS) in women with breast intraepithelial neoplasia in a 10-year follow-up of the TAM-01 trial (NCT01357772).
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast …
Oct 24, 2024 · The American Society of Clinical Oncology (ASCO) recently announced guidelines outlining a preference for abemaciclib (Verzenio) over ribociclib (Kisqali) for the treatment of patients with node-positive, high-risk, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 1. The recommendation is based on findings from the monarchE (NCT03155997 ...
PD-L1 CPS Score Could Direct Treatment Decisions in Recurrent ...
Apr 1, 2022 · PD-L1 combined positive score (CPS) may serve to predict whether a patient with PD-L1–expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) will receive optimal benefit with pembrolizumab (Keytruda) alone vs in combination with chemotherapy or with cetuximab (Erbitux) plus chemotherapy, according to an efficacy subgroup analysis of the phase 3 KEYNOTE-048 trial ...
20 Inspirational Quotes for Cancer Survivors, Fighters, and Caregivers
Aug 25, 2015 · The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.
ctDNA Has High Sensitivity ESR1 Mutations in Metastatic Breast …
Oct 14, 2024 · After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression on frontline therapy, it is essential that they be tested for an ESR1 mutation. ctDNA testing is the best way to do that, according to a physician assistant from Maimonides Cancer Center.. About ESR1 Mutations in Metastatic Breast Cancer
Belantamab Mafodotin, KRd Is Promising in Relapsed/Refractory …
Oct 2, 2024 · Belantamab mafodotin-blmf (Blenrep) plus carfilzomib, lenalidomide (Revlimid), and dexamethasone (a regimen known as KRd) demonstrated early evidence of deep responses, as well as a manageable adverse event profile in previously treated patients with multiple myeloma, according to data from a phase 1 trial (NCT04822337), presented at the 21st International Myeloma Society Annual Meeting. 1
Bispecific Antibodies Are ‘Not Your Typical Chemotherapy’ in …
Nov 18, 2024 · The use of bispecific antibodies have brought landmark change for the treatment of relapsed/refractory multiple myeloma, and tend to be well-tolerated, explained Carrie Lechtenberger, APRN, FNP-C, CCM, OCN, CBCN.
Opinion: The Media May Have Oversold AOH1996, City of Hope's …
Sep 20, 2023 · AOH1996, a drug named in honor of Anna Olivia Healy, is being tested in a phase 1 trial. As nurses, we must help our patients understand that phase 1 trials represent very early research.
Navigating Fertility Preservation Options for Patients Undergoing ...
Aug 20, 2024 · As cancer treatment can affect fertility in both men and women, oncology nurses and advanced practice providers play a crucial role in educating patients about fertility presentation options, if they are interested.